Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
This article is Part III of a series. View parts I and II:Evolving Paradigms in Squamous NSCLC> >
Sunvozertinib Shows Activity, Tolerable Safety in EGFR Exon20 Insertion-Positive NSCLC
June 6th 2023Phase 2 results have placed a novel EGFR exon 20 insertion inhibitors in the realm of possibilities for future treatment of previously-treated non–small cell lung cancer with EGFR exon 20 insertions in the tumor tissue.
Read More
Datopotamab Deruxtecan/Pembrolizumab Combo Show Anti-tumor Activity in Advanced NSCLC
June 6th 2023New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512